ストックスクリーナーアプリを入手
14.60
9.60%
-1.55
プレマーケット:
14.57
-0.03
-0.21%
前日終値:
$16.15
開ける：
$15.49
24時間の取引高:
1.91M
Relative Volume:
0.80
時価総額：
$2.40B
収益：
-
当期純損益:
$-412.89M
株価収益率:
-3.7824
EPS:
-3.86
ネットキャッシュフロー:
$-361.93M
1週間 パフォーマンス:
-6.05%
1か月 パフォーマンス:
-23.00%
6か月 パフォーマンス:
+8.31%
1年 パフォーマンス:
+18.51%
1日の値動き範囲:
$14.58
$15.81
1週間の範囲:
$14.00
$16.34
52週間の値動き範囲:
$6.36
$25.00
Dyne Therapeutics Inc Stock (DYN) Company Profile
Compare DYN vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
14.60 | 2.66B | 0 | -412.89M | -361.93M | -3.86 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.72 | 46.83B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.04 | 34.79B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-10 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-10-10 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-08-25 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | 開始されました | Bernstein | Mkt Perform |
| 2025-06-11 | 再開されました | Raymond James | Outperform |
| 2025-06-02 | 再開されました | Oppenheimer | Outperform |
| 2025-05-29 | 開始されました | Evercore ISI | Outperform |
| 2025-03-12 | 開始されました | BMO Capital Markets | Outperform |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-13 | 開始されました | Robert W. Baird | Outperform |
| 2024-11-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-10-24 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-05-21 | 繰り返されました | Chardan Capital Markets | Buy |
| 2024-04-30 | 開始されました | Morgan Stanley | Overweight |
| 2024-02-20 | 開始されました | H.C. Wainwright | Buy |
| 2023-02-27 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | 開始されました | Oppenheimer | Outperform |
| 2023-01-26 | 開始されました | Guggenheim | Buy |
| 2022-07-20 | 開始されました | Chardan Capital Markets | Buy |
| 2022-07-12 | 開始されました | Raymond James | Outperform |
| 2020-10-12 | 開始されました | JP Morgan | Overweight |
| 2020-10-12 | 開始されました | Jefferies | Buy |
| 2020-10-12 | 開始されました | Piper Sandler | Overweight |
| 2020-10-12 | 開始されました | Stifel | Buy |
すべてを表示
Dyne Therapeutics Inc (DYN) 最新ニュース
Chardan Capital Maintains Buy Rating on Dyne Therapeutics (DYN) - GuruFocus
HC Wainwright & Co. Lowers Price Target for Dyne Therapeutics (D - GuruFocus
Decoding Dyne Therapeutics Inc (DYN): A Strategic SWOT Insight - GuruFocus
DYN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Overweight Maintained for Dyne Therapeutics (DYN) by Morgan Stanley March 2026 - Meyka
Raymond James reiterates Dyne Therapeutics stock rating on FDA pathway By Investing.com - Investing.com Canada
Dyne Therapeutics (NASDAQ:DYN) Shares Down 6.6% After Earnings Miss - MarketBeat
Morgan Stanley cuts Dyne Therapeutics stock price target on model update - Investing.com Canada
Dyne’s Larger 2025 Loss And New Shelf Registration Might Change The Case For Investing In Dyne Therapeutics (DYN) - simplywall.st
Dyne Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Dyne Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Dyne Therapeutics Posts Wider Loss In Q4 - Nasdaq
Dyne Therapeutics (DYN) Beats Q4 EPS Expectations - GuruFocus
Dyne Therapeutics Q4 Net Loss Narrows - marketscreener.com
Dyne Therapeutics (DYN) Approaches Key Transformation Phase - GuruFocus
DYNE THERAPEUTICS ($DYN) Releases Q4 2025 Earnings - Quiver Quantitative
Dyne Therapeutics (NASDAQ:DYN) Posts Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Dyne Therapeutics (NASDAQ: DYN) pairs 2025 loss with pivotal DMD and DM1 milestones - Stock Titan
Dyne Therapeutics eyes 2027 Duchenne drug launch, backed by $1.1B cash - Stock Titan
Dyne Therapeutics 2025 10-K: $0 Revenue, Net Loss $446.2M - TradingView
Dyne Therapeutics (NASDAQ: DYN) advances FORCE-based neuromuscular pipeline - Stock Titan
DYNDyne Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Oppenheimer Upgrades Dyne Ahead of Avidity's Upcoming Trial Results - Intellectia AI
Dyne Therapeutics, Inc. $DYN Holdings Raised by JPMorgan Chase & Co. - MarketBeat
DYN SEC FilingsDyne Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Sarepta CEO To Jump Ship After 'Tumultuous' Year - Benzinga
Dyne Announces Positive Results from DELIVER Trial for DMD at MDA Conference - Intellectia AI
Dyne Therapeutics earnings ahead: DMD filing timeline in focus - Investing.com Australia
Dyne Therapeutics to Participate in Upcoming Investor Conferences - Investing News Network
Biotech Dyne Therapeutics heads to three March investor conferences - Stock Titan
Dyne Therapeutics (DYN) Stock Analysis: Exploring a 153% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Price-Driven Insight from (DYN) for Rule-Based Strategy - Stock Traders Daily
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference - Sahm
Dyne Therapeutics (DYN) to Showcase Key Developments at 2026 MDA Conference - GuruFocus
Dyne Therapeutics to Showcase Positive Results from DELIVER Trial and Phase 3 Trial Design at 2026 MDA Clinical & Scientific Conference - Quiver Quantitative
New heart-lung data in rare muscle diseases: inside Dyne’s 2026 trial push - Stock Titan
Dyne Therapeutics Announces Upcoming Presentations Across - GlobeNewswire
Aberdeen Group plc Purchases 72,770 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Aug PostEarnings: Is Dyne Therapeutics Inc a turnaround storyBreakout Watch & Entry Point Confirmation Signals - baoquankhu1.vn
Dyne Therapeutics (DYN) to Release Earnings on Thursday - MarketBeat
Bullish Analyst Opinion on Dyne (DYNE) Follows Rare Disease Drug Progress in Japan - Finviz
VIX Spike: What is Dyne Therapeutics Incs 5 year growth outlookIPO Watch & Weekly Sector Rotation Insights - baoquankhu1.vn
Dyne Therapeutics, Inc. (DYN) Stock Analysis: Exploring a 151% Upside Potential in Biotech - DirectorsTalk Interviews
Weekly Trades: Can Dyne Therapeutics Inc disrupt its industry2025 Bull vs Bear & Weekly High Return Forecasts - baoquankhu1.vn
Dyne Therapeutics (DYN) Attains Orphan Drug Designation From Japanese Ministry - Finviz
Dyne Therapeutics announces $300M proposed public offering - MSN
Can Dyne Therapeutics Inc. disrupt its industryWeekly Risk Summary & Daily Profit Focused Stock Screening - mfd.ru
Earnings Risk: Is Dyne Therapeutics Inc gaining market shareJuly 2025 Movers & Verified Momentum Stock Watchlist - baoquankhu1.vn
What is Dyne Therapeutics Inc. s 5 year growth outlookChart Signals & Verified Swing Trading Watchlists - mfd.ru
Facioscapulohumeral Muscular Dystrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics - Barchart.com
Dyne Therapeutics Inc (DYN) 財務データ
収益
当期純利益
現金流量
EPS
5.71%
0.02%
大文字化:
|
ボリューム (24 時間):